TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00550680
Drug: Methoxy polyethylene glycol-epoetin beta
Normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
Study: NCT00923130
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
Study: NCT00923130
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
Study: NCT04020601
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic injection
Study: NCT04020601
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection
Study: NCT03483753
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min
Study: NCT01651039
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
Study: NCT03790345
Drug: Cobalamin
Normalized name: Cobalamin
DrugBank: Cobalamin (DB14098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant daily treatment with 2mg of cobalamin
Study: NCT02997150
Drug: IL-2 Low dose
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection
Study: NCT03693625
Drug: GDC-0853
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
Study: NCT04632758
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, 250mg, BID
Study: NCT02258451
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
Study: NCT02258451
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 25 mg tablet once daily after a meal.
Study: NCT02258451
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice.
Study: NCT01498003
Drug: tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
Study: NCT01498003
Drug: normal saline solution
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: same use as tirofiban
Study: NCT03748303
Drug: Allopregnanolone
Normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of weekly IM injections of Allopregnanolone.
Study: NCT04206332
Drug: VRC-MALMAB0100-00-AB
Normalized name: AB-8939
DrugBank: AB-8939 (DB17115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
Study: NCT04124913
Drug: Dydrogesterone 10 MG Oral Tablet
Normalized name: dydrogesterone 10 MG Oral Tablet
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
Study: NCT04124913
Drug: Progesterone Vaginal Gel [Crinone]
Normalized name: progesterone Vaginal Gel [Crinone]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal progesterone gel 90 mg once a day for luteal phase support
Study: NCT00977522
Drug: PF-03463275
Normalized name: PF-03463275
DrugBank: PF-03463275 (DB11993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Controlled Release tablet BID for 12 weeks
Study: NCT00520923
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
Study: NCT00520923
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Study: NCT00520923
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Study: NCT00520923
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Study: NCT00520923
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
Study: NCT04066491
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
Study: NCT03988803
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet
Study: NCT03988803
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film coated tablet
Study: NCT04066491
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
Study: NCT01053871
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conscious sedation using propofol
Study: NCT00389792
Drug: ATI-2042
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: no intervention
Study: NCT00389792
Drug: ATI-2042 200 mg
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
Study: NCT01805531
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
Study: NCT02922777
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 given IV every 21 days
Study: NCT02670772
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
Study: NCT02670772
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
Study: NCT00061321
Drug: Nevirapine and mulitvitamins
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
Study: NCT03031184
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03680053
Drug: Duphaston
Normalized name: Duphaston
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
Study: NCT03680053
Drug: Cetrorelix
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Study: NCT02527109
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00633256
Drug: Cycloserine
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
Study: NCT00309881
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00309881
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00851877
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is an anti-cancer chemotherapy drug
Study: NCT00851877
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel albumin-stabilized nanoparticle formulation
Study: NCT00417222
Drug: olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 to 40mg P.O. daily until the end of the study
Study: NCT00876395
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
Study: NCT00876395
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab, 2 mg/kg weekly was used intravenously.
Study: NCT00876395
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel, 80 mg/m2 weekly was used intravenously.
Study: NCT00625209
Drug: recombinant human activated protein C and placebos
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
Study: NCT03542006
Drug: Brinzolamide Ophthalmic
Normalized name: brinzolamide ophthalmic
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical brinzolamide given bd for 3 months
Study: NCT03988530
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).
Study: NCT03584919
Drug: Cefuroxime Axetil 500Mg Tab
Normalized name: CEFUROXIME AXETIL 500MG TAB
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received cefuroxime axetil 500 milgrams bid for 15 days
Study: NCT01651039
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
Study: NCT03627091
Drug: Ontamalimab
Normalized name: Ontamalimab
DrugBank: Ontamalimab (DB15298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.
Study: NCT01334333
Drug: Tacrolimus - Prograf® twice daily formulation
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
Study: NCT01334333
Drug: Tacrolimus - Advagraf® once daily formulation
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
Study: NCT00148837
Drug: Peg-interferon alpha 2b (drug)
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00148837
Drug: Ribavirin (drug)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00148837
Drug: Prazosin (drug)
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00614471
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg po daily for 24 weeks
Study: NCT00614471
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg po daily from week 13 to week 36
Study: NCT00614471
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms sc/week for 48 weeks
Study: NCT00614471
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms sc/week from week 21 to week 68
Study: NCT00089661
Drug: AMG 162 / Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
Study: NCT01237730
Drug: cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use the cefuroxime as prophylaxis.
Study: NCT00268489
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03227471
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVA tablet for oral administration
Study: NCT03227471
Drug: VX-445
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-445 tablet for oral administration.
Study: NCT03227471
Drug: TEZ
Normalized name: Otezla
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet for oral administration.
Study: NCT03227471
Drug: VX-561
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT03227471
Drug: VX-445
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-445 IV injection
Study: NCT00300911
Drug: Rosiglitazone(drug), cardiac adverse effects
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00761306
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 or 10 mg/day; tablets; orally
Study: NCT02681536
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02681536
Drug: Combined oral contraceptive pills
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04185103
Drug: Sacubitril-Valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
Study: NCT00833053
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
Study: NCT02077465
Drug: Andecaliximab
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg andecaliximab administered intravenously
Study: NCT02077465
Drug: Placebo to match Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match andecaliximab administered intravenously
Study: NCT01828697
Drug: Low dose nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose nadroparin:~* \< 100 kg: 2850 IU subcutaneously once-daily~* 100 kg and above: 3800 IU subcutaneously once-daily
Study: NCT01828697
Drug: Intermediate dose nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate weight-adjusted dose nadroparin:~* \< 50 kg: 3800 IU subcutaneously once-daily;~* 50 to \< 70 kg: 5700 IU subcutaneously once-daily;~* 70 to \< 100 kg: 7600 IU subcutaneously once-daily;~* 100 kg or above: 9500 IU subcutaneously once-daily.
Study: NCT00833053
Drug: Infliximab and methotrexate
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
Study: NCT00522145
Drug: XL647
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
Study: NCT01828697
Drug: Low dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose enoxaparin:~* \< 100 kg: 40 mg subcutaneously once-daily~* 100 kg and above: 60 mg subcutaneously once-daily
Study: NCT01785160
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: low dose oral administration
Study: NCT01785160
Drug: Faldaprevir
Normalized name: Faldaprevir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium dose oral administration
Study: NCT00540137
Drug: nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg once daily
Study: NCT01828697
Drug: Intermediate dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate weight-adjusted dose enoxaparin:~* \< 50 kg: 60 mg subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 80 mg subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 100 mg subcutaneously once-daily, or;~* 100 kg or above: 120 mg subcutaneously once-daily.
Study: NCT01828697
Drug: Low dose dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose dalteparin:~* \< 100 kg: 5000 IU subcutaneously once-daily~* 100 kg and above: 7500 IU subcutaneously once-daily
Study: NCT01828697
Drug: Intermediate dose dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate weight-adjusted dose dalteparin:~* \< 50 kg: 7500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 10000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 12500 IU subcutaneously once-daily, or;~* 100 kg or above: 15000 IU subcutaneously once-daily.
Study: NCT01828697
Drug: Fixed low dose tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose tinzaparin:~* \< 100 kg: 3500 IU subcutaneously once-daily~* 100 kg and above: 4500 IU subcutaneously once-daily
Study: NCT01828697
Drug: Intermediate dose tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate weight-adjusted dose tinzaparin:~* \< 50 kg: 4500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 7000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 10000 IU subcutaneously once-daily, or;~* 100 kg or above: 12000 IU subcutaneously once-daily.
Study: NCT06055101
Drug: DEXMEDETOMIDINE
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water.